en فاکتور رشد شبه انسولینی-1 در روز دوم سیکل با پیامد سیکل های کمک باروری: یک مطالعه مقطعی Fertility & Infertility Original Article Original Article <div style="text-align: justify;"><span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">مقدمه: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">اختصاصی کردن روش&shy;های درمان کمک باروری با توجه به شرایط هر فرد، روشی مؤثر برای بهبود نتایج درمان است که خود نیازمند یک پیشگویی&shy;کننده قابل اعتماد و کارآمد برای پاسخ تخمدان می&shy;باشد. برخی از مطالعات نشان داده&shy;اند فاکتور رشد شبه انسولینی 1 (</span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">) می</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">تواند یک فاکتور پیش&shy;بینی&shy;کننده قابل اعتماد باشد.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">هدف: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">بررسی رابطه بین سطوح سرمی </span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> در روز دوم سیکل قاعدگی و</span></span><span lang="FA" style="font-size:10.0pt"><span b="" mitra="" style="font-family:"> پیامد </span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">سیکل&shy;های کمک باروری.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">مواد و روش &shy;ها: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">در این مطالعه مقطعی ،سطح خونی </span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> در 175 زن 44-18 ساله کاندید انجام </span></span><span dir="LTR" style="font-size:10.0pt">ART</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">در روز دوم سیکل قاعدگی اندازه</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">گیری شد. بیماران با پروتکل آنتاگونیست درمان شدند. بازیافت اووسیت انجام شد. و براساس تعداد اووسیت بدست آمده بیماران به سه گروه تقسیم شدند گروه پاسخ ضعیف (تعداد اووسیت کمتر از 5) پاسخ نرمال (تعداد اووسیت 15-5) پاسخ بالا (تعداد اووسیت بیشتر از 15) و ارتباط پیامد سیکل&shy;های کمک&shy;باروری و سطح خونی </span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">بر حسب تعداد اووسیت بررسی شد.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">نتایج: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">سطح سرمی<b> </b></span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> در گروه پاسخ&shy;دهنده&shy;های ضعیف بالاتر از دو گروه دیگر بود هر چند تفاوت از نظر آماری معنی&shy;دار نبود. (41/0 </span></span><span lang="FA" style="font-size:10.0pt">= </span><span dir="LTR" style="font-size:10.0pt">p</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">). در گروه&nbsp; &nbsp;پاسخ&shy;دهنده ضعیف، سطح <a name="_Hlk123909562">سرمی</a> </span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">در افراد با تعداد اوسیت صفر و افرادی که سیکل آنها کنسل شده بود در مقایسه با سایر افراد گروه پاسخ ضعیف تفاوت معنی&shy;داری نداشت. ارتباط معنی&shy;داری بین سطح سرمی </span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">و سن, شاخص توده بدنی, تعداد</span></span><span dir="LTR" style="font-size:10.0pt">PN</span> &nbsp;<span dir="LTR" style="font-size:10.0pt">2</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">و تعداد جنین وجود نداشت اما بین سطح سرمی </span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">با </span></span><span dir="LTR" style="font-size:10.0pt">AMH</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">ارتباط معکوس مشاهده شد. </span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">نتیجه&shy; گیری:</span></span></b> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">با توجه به نتایج مطالعه ما، سطح خون </span></span><span dir="LTR" style="font-size:10.0pt">IGF-1</span><span style="font-size:11.0pt"><span b="" mitra="" style="font-family:"> ممکن است نتواند نتایج </span></span><span dir="LTR" style="font-size:10.0pt">ART</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">را پیش</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">بینی کند. با توجه به اهمیت موضوع و تناقض مطالعات قبلی، انجام مطالعات بیشتر در این زمینه ضروری به نظر می</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">رسد.</span></span><span dir="LTR" style="font-size:11.0pt"><span style="font-family:"Arial","sans-serif""></span></span></span></span></span></span></span></div> <pre style="text-align:justify"> <span style="font-family:Times New Roman;"><span style="font-size:10pt"><span style="background:white"><b><span lang="EN" style="font-size:12.0pt">Background:</span></b> <span style="font-size:12.0pt">Individualized assisted reproductive techniques (ART) can improve ART</span> <span style="font-size:12.0pt">outcomes. Some studies suggested using insulin-like growth factor-1 (IGF-1) level on cycle day 2 for individualized ART.</span></span></span></span><span style="font-size:10pt"><span style="background:white"><span courier="" new="" style="font-family:"><span style="font-size:12.0pt"><span style="font-family:"Times New Roman","serif""></span></span></span></span></span></pre> <pre style="text-align:justify"> <span style="font-family:Times New Roman;"><span style="font-size:10pt"><span style="background:white"><b><span lang="EN" style="font-size:12.0pt">Objective:</span></b><span lang="EN" style="font-size:12.0pt"> To investigate the relationship between serum levels of IGF-1 on day 2 of the cycle and ART outcomes. </span></span></span></span></pre> <pre style="text-align:justify"> <span style="font-family:Times New Roman;"><span style="font-size:10pt"><b><span style="font-size:12.0pt">Materials and Methods: </span></b><span style="font-size:12.0pt">In this cross-sectional study, cycle day 2 serum levels of IGF-1 were measured in 175 women aged between 18-44 yr as candidates for in vitro fertilization or intracytoplasmic sperm injection. All participants received antagonist protocol, and the relationship between serum levels of IGF-1 and ART outcomes according to the number of oocytes were investigated; poor responders (oocytes < 5), normal responders (oocytes 5-15), and hyper responders (oocytes > 15). </span></span></span></pre> <pre style="text-align:justify"> <span style="font-family:Times New Roman;"><span style="font-size:10pt"><b><span style="font-size:12.0pt">Results: </span></b><span style="font-size:12.0pt">Poor responders had higher serum level of IGF-1 when compared with normal and hyper-responders; however,<b> </b>this difference was not statistically significant (p = 0.41). The serum levels of IGF-1 in women with zero retrieved oocytes and those cycles that were canceled for the inappropriate ovarian response were not significantly different compared to other women in the group of poor responders. An inverse relationship was observed between the serum level of IGF-1 and anti-Mullerian hormone. Furthermore, no significant relationship between serum level of IGF-1 with age, body mass index, number of 2 pronucleus, and number of embryos was observed. </span></span></span></pre> <pre style="text-align:justify"> <span style="font-family:Times New Roman;"><span style="font-size:10pt"><b><span style="font-size:12.0pt">Conclusion:</span></b><span style="font-size:12.0pt"> According to our results, the serum levels of IGF-1 may not be able to predict ART outcomes. It seems necessary to conduct more studies with larger sample size. </span></span></span></pre> <pre style="text-align:justify"> </pre> <pre style="text-align:justify"> <span style="font-family:Times New Roman;"><span style="font-size:10pt"><span style="font-family:"Times New Roman","serif""></span></span></span></pre> <pre style="text-align:justify"> </pre> <pre style="text-align:justify"> </pre> سطح خونی IGF-1, اووسیت بازیافتی, پیامد سیکل های کمک باروری, پاسخ دهنده ضعیف. Insulin-like growth factor-1, Poor ovarian response, Oocyte retrieval, Assisted reproductive techniques outcome. 139 146 http://ijrm.ir/browse.php?a_code=A-10-2316-1&slc_lang=en&sid=1 Fariba Abbasi faribaabbasi5759@gmail.com 0000-0001-6846-7369 No Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Robab Davar r_davar@yahoo.com 0000-0002-5296-5707 No Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Farimah Shamsi farimah.shamsi@gmail.com 0000-0002-8812-0765 No Center for Healthcare Data Modeling, Department of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Saeideh Dashti saeideh_dashti@yahoo.com 0000-0001-7089-0772 Yes Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.